Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

LGND : 103.27 (-1.94%)
BMRN : 89.79 (-0.50%)
ZTS : 53.38 (-0.17%)
SAGE : 61.93 (-3.33%)
TEVA : 35.97 (-1.86%)
ICPT : 122.79 (-2.12%)
ALXN : 130.83 (+0.72%)
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.

CELG : 119.27 (-0.14%)
SRPT : 30.38 (+5.93%)
MDCO : 52.22 (-2.08%)
BMRN : 89.79 (-0.50%)
GILD : 68.83 (-0.66%)
AMGN : 172.61 (-0.31%)
ALXN : 130.83 (+0.72%)
Forget Alexion, Buy these 4 Biotech Stocks Instead

We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

CELG : 119.27 (-0.14%)
LGND : 103.27 (-1.94%)
EXEL : 22.62 (-2.12%)
FATE : 4.24 (-3.20%)
ALXN : 130.83 (+0.72%)
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS

Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.

IRWD : 16.87 (-1.46%)
EXAS : 22.69 (+1.25%)
ZTS : 53.38 (-0.17%)
MNTA : 15.10 (-5.92%)
TEVA : 35.97 (-1.86%)
ALXN : 130.83 (+0.72%)
Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y

Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.

EXAS : 22.69 (+1.25%)
SNSS : 4.25 (unch)
GSK : 41.03 (-1.44%)
ALXN : 130.83 (+0.72%)
Alexion (ALXN) Misses on Q4 Earnings and Revenues

Alexion missed on earnings expectations in the fourth quarter of 2016.

ALXN : 130.83 (+0.72%)
Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017

--Global Soliris(R) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS

ALXN : 130.83 (+0.72%)
5 Stocks to Watch that Report Earnings Tomorrow

Arista Networks ( ANET ): Arista Networks roared through 2016 only to hit a massive snag at the start of the new year. In late January, the CBP revoked an earlier court ruling over an ongoing patent infringement...

WEN : 13.69 (-3.11%)
MGM : 26.46 (-1.82%)
ANET : 121.80 (-0.67%)
H : 52.20 (-2.30%)
LVS : 51.97 (-0.13%)
SPY : 236.28 (-0.09%)
ALXN : 130.83 (+0.72%)
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More

The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.

AGIO : 48.99 (-2.80%)
RARE : 78.18 (+1.64%)
ZTS : 53.38 (-0.17%)
GILD : 68.83 (-0.66%)
REGN : 370.22 (-0.37%)
GSK : 41.03 (-1.44%)
SNY : 42.52 (-0.56%)
ALXN : 130.83 (+0.72%)
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

INCY : 121.36 (-0.82%)
ACOR : 25.25 (-0.20%)
AMAG : 23.90 (unch)
ALXN : 130.83 (+0.72%)
Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results on Thursday, February 16, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2016 on Thursday, February...

ALXN : 130.83 (+0.72%)
The Zacks Analyst Blog Highlights: ExxonMobil, Procter & Gamble, Micron, Macy's and Alexion Pharmaceuticals

The Zacks Analyst Blog Highlights: ExxonMobil, Procter & Gamble, Micron, Macy's and Alexion Pharmaceuticals

XOM : 80.93 (-1.17%)
PG : 91.44 (-0.25%)
MU : 23.75 (-0.08%)
M : 32.36 (+0.22%)
ALXN : 130.83 (+0.72%)
Research Reports on Exxon, P&G and the Q4 Earnings Season

Research Reports on Exxon, P&G and the Q4 Earnings Season

XOM : 80.93 (-1.17%)
PG : 91.44 (-0.25%)
MU : 23.75 (-0.08%)
PM : 104.53 (-0.03%)
M : 32.36 (+0.22%)
ALXN : 130.83 (+0.72%)
4 Top Biotech Mutual Funds for 2017

Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance

CELG : 119.27 (-0.14%)
IBB : 290.31 (-0.85%)
HBGHX : 22.83 (+0.18%)
FBT : 100.48 (-1.23%)
JFNAX : 49.16 (unch)
GILD : 68.83 (-0.66%)
SWHFX : 23.16 (+0.35%)
AMGN : 172.61 (-0.31%)
XBI : 67.79 (-1.77%)
ALXN : 130.83 (+0.72%)
BIIB : 287.63 (+0.25%)
FBIOX : 199.22 (-0.57%)
FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) & Lead Plaintiff Deadline - January 17, 2017

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ:ALXN)...

ALXN : 130.83 (+0.72%)
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

MYL : 42.00 (-0.71%)
ENDP : 12.89 (-2.27%)
MRK : 65.29 (-0.29%)
AGN : 246.32 (-0.34%)
VRX : 16.35 (-0.30%)
ALXN : 130.83 (+0.72%)
BIIB : 287.63 (+0.25%)
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline - January 17, 2017

NEW YORK, NY / ACCESSWIRE / January 11, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company")...

ALXN : 130.83 (+0.72%)
Alexion (ALXN) Files for Label Expansion of Soliris in U.S., EU

Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.

OREX : 4.20 (-0.94%)
KITE : 53.68 (-2.42%)
EPZM : 12.05 (-2.03%)
ALXN : 130.83 (+0.72%)
Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized Myasthenia Gravis Medicine

Upcoming AWS Coverage on Jazz Pharmaceuticals

JAZZ : 134.95 (-0.72%)
ALXN : 130.83 (+0.72%)
Alexion Blood Disorder Drug Gets Orphan Designation in U.S.

Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

ABUS : 2.60 (-3.70%)
OREX : 4.20 (-0.94%)
EPZM : 12.05 (-2.03%)
ALXN : 130.83 (+0.72%)

Van Meerten Stock Picks

5 NASDAQ 100 Stocks for Momentum Investors
Today I wanted to find the 5 NASDAQ 100 stocks that would be of interest to Momentum Investors.
AVGO +1.41 , AAPL +0.41 , AMAT -0.07 , SYMC -0.21 , EA -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH17 -0.17% ) are down -0.15% and European stocks fell back from a 14-month high and are down -0.23% . Long liquidation ahead of today's minutes of the Jan 31-Feb 1 FOMC meeting weighed on... Read More

Chart of the Day

Patheon (PTHN) is the Barchart Chart of the Day.  The Dutch Pharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha of 31.40+ and gained 28.25% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Wednesday 1 3/4 cents higher in most contracts. South Korea purchased 55,000 MT of US corn earlier this morning with delivery May 10-25. Private exporters reported a cancellation to the USDA this morning of 136,000 MT of optional ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.